Biosimilar
VIDEO: Specialist highlights benefits of new-generation anti-VEGFs
SEVILLE, Spain — In this Healio Video Perspective from the Congress on Controversies in Ophthalmology, Patricia Udaondo, MD, PhD, highlights the meeting’s debate sessions on new anti-VEGF therapies.
Yuflyma becomes fourth Humira biosimilar to receive interchangeability status
The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.
FDA grants approval to two more denosumab biosimilars
The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, according to an industry press release.
FDA approves omalizumab biosimilar Omlyclo
The FDA approved Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of multiple conditions including asthma and food allergy, according to an agency press release.
Two new denosumab biosimilars earn FDA approval
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, according to a press release from Celltrion.
First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.
ACR cheers ‘positive first step’ in reforming prior authorization for Medicare
Prior authorization reforms, increased biosimilar access and the future of the Medicare drug price negotiation program are among the American College of Rheumatology’s top concerns in a letter recently submitted to CMS.
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes.
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
2024’s money moves: Healio Rheumatology tracks specialty pharmacies, work-life balance
Money talks. And in the world of medicine, what it has to say has important implications for patients and providers alike.